^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gemcitabine

    i
    Other names: dFdC, LY 188011, LY188011, LY-188011
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1d
    Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, CStone Pharmaceuticals | Trial completion date: Jun 2029 --> Dec 2029 | Trial primary completion date: Jun 2028 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • oxaliplatin • Cejemly (sugemalimab) • Oncaspar liquid (pegaspargase)
    1d
    Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (clinicaltrials.gov)
    P3, N=808, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv)
    1d
    Carolyn-USA: A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=144, Recruiting, Engeneic Pty Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    gemcitabine • albumin-bound paclitaxel
    1d
    Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL (clinicaltrials.gov)
    P=N/A, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New trial
    |
    gemcitabine • Rituxan (rituximab) • ifosfamide • oxaliplatin • etoposide IV • mesna • Duoenda (mitoxantrone liposomal)
    2d
    Uncommon Presentation of Primary Bladder Signet Ring Cell Carcinoma With Peritoneal Carcinomatosis: A Rare Case Report. (PubMed, Case Rep Urol)
    Despite peritoneal carcinomatosis, the patient responded to cisplatin/gemcitabine chemotherapy and immunotherapy, demonstrating tumor shrinkage on follow-up imaging. This case highlights the diagnostic challenges of SRCC due to its nonspecific symptoms and potential histological overlap with other metastatic gastrointestinal tumors. Early recognition and a multidisciplinary approach are critical for improving patient outcomes.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CDX2 (Caudal Type Homeobox 2)
    |
    PD-L1 expression • ER negative
    |
    cisplatin • gemcitabine
    2d
    ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, Washington University School of Medicine | N=114 --> 31 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation
    |
    gemcitabine • docetaxel • Hepacid (pegargiminase)
    2d
    LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Nov 2033 | Trial primary completion date: Dec 2025 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    2d
    Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (clinicaltrials.gov)
    P2, N=27, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    2d
    A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Jul 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Datroway (datopotamab deruxtecan-dlnk)
    2d
    Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    gemcitabine • docetaxel • hydroxychloroquine
    2d
    Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Dec 2026
    Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel • metformin